7 468

Cited 4 times in

Regression of uveal melanoma after RU-106 brachytherapy and thermotherapy based on metabolic activity measured by positron emission tomography/computed tomography

Authors
 CHRISTOPHER S. LEE  ;  SUNG C. LEE  ;  KYUNGSIK LEE  ;  HEE J. KWON  ;  JEONG H. YI  ;  ARTHUR CHO 
Citation
 RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, Vol.34(1) : 182-187, 2014 
Journal Title
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
ISSN
 0275-004X 
Issue Date
2014
MeSH
Adult ; Aged ; Aged, 80 and over ; Brachytherapy* ; Female ; Fluorodeoxyglucose F18 ; Humans ; Hyperthermia, Induced* ; Male ; Melanoma/diagnostic imaging ; Melanoma/metabolism ; Melanoma/radiotherapy* ; Melanoma/therapy* ; Middle Aged ; Prognosis ; Radiopharmaceuticals ; Retrospective Studies ; Ruthenium Radioisotopes/therapeutic use* ; Tomography, Emission-Computed, Single-Photon* ; Uveal Neoplasms/diagnostic imaging ; Uveal Neoplasms/metabolism ; Uveal Neoplasms/radiotherapy* ; Uveal Neoplasms/therapy*
Keywords
PET/CT ; prognosis ; tumor regression ; uveal melanoma
Abstract
PURPOSE: To evaluate regression rates of uveal melanoma after combined Ru-106 plaque radiotherapy and thermotherapy according to metabolic activity measured by positron emission tomography/computed tomography imaging.
METHODS: A retrospective medical chart review was conducted on 26 patients with uveal melanoma who underwent pretreatment whole-body positron emission tomography/computed tomography and received combined plaque radiotherapy and thermotherapy between 2006 and 2011. Tumors were classified as metabolically active and inactive based on the positron emission tomography/computed tomography imaging and compared with tumor height regression rates after treatment.
RESULTS: Before treatment, the median tumor thickness was 8.8 mm for metabolically active tumors (7 eyes) and 5.0 mm for metabolically inactive tumors (19 eyes). The median tumor thicknesses with respect to the original thickness at 3, 6, and 12 months after treatment were 88%, 78%, and 64% for metabolically active tumors and 95%, 89%, and 81% for metabolically inactive tumors, respectively. The monthly tumor regression rates during the first 3 months (4.2% vs. 1.7%, P = 0.022) and the overall monthly tumor regression rates (3.0% vs. 1.5%, P = 0.041) were significantly higher for metabolically active tumors versus inactive tumors. Two patients with positive metabolic activity developed metastatic diseases 2 years after treatment, whereas no patient with negative metabolic activity developed metastatic disease during the study period.
CONCLUSION: Positive metabolic activity of uveal melanoma based on the positron emission tomography/computed tomography was significantly associated with rapid initial tumor regression after combined plaque radiotherapy and thermotherapy, suggesting a prognostic value for this diagnostic approach.
Full Text
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00006982-201401000-00025&LSLINK=80&D=ovft
DOI
10.1097/IAE.0b013e31829479fb
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Nuclear Medicine (핵의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers
Yonsei Authors
Kwon, Hee Jung(권희정)
Lee, Sung Chul(이성철) ORCID logo https://orcid.org/0000-0001-9438-2385
Lee, Christopher Seungkyu(이승규) ORCID logo https://orcid.org/0000-0001-5054-9470
Yi, Jung Ho(이정호)
Cho, Arthur Eung Hyuck(조응혁) ORCID logo https://orcid.org/0000-0001-8670-2473
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/98013
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links